Connect Biopharma Completes Enrollment of CBP-201 Global Phase 2 Clinical Trial in Moderate-to-Severe Atopic Dermatitis,

The global, randomized, double-blind, placebo-controlled, dose-ranging clinical trial to assess the efficacy … that 26.1 million people in the United States have AD, of which 6.6 million …, The global, randomized, double-blind, placebo-controlled, dose-ranging clinical trial to assess the efficacy … that 26.1 million people in the United States have AD, of which 6.6 million …, Read More

Scroll to Top